Biotech AI Visibility: An Earned Media Strategy

A biotech AI visibility earned media strategy should start with the question an investor or potential partner needs answered, not a list of publications to target. Choose the scientific narrative the company can substantiate, make its public evidence understandable, and seek relevant third-party reporting. Then audit whether AI answers describe the company accurately and connect their claims to the right sources.

The goal is a credible account of what the company does and why it belongs in a particular conversation. A mention is not a recommendation. A citation is not validation of a clinical claim. Neither proves that media coverage changed a financing decision.

Choose the narrative before choosing the outlet

Start with one decision: what should a prospective investor or partner understand before deciding whether to investigate the company further?

Possible narratives include a platform's approach to a defined research problem, the scope of an announced collaboration, or the distinction between a company's modality and adjacent approaches. These are proposed starting points, not claims that any particular company has earned the position.

Write the narrative as a question and a bounded answer. For example: “How does this platform approach its stated target, and what public evidence describes that approach?” Keep the answer specific enough to check. Distinguish the platform description from a product claim, a research hypothesis from a demonstrated result, and a development milestone from an expected outcome.

That boundary is the editorial brief. If the narrative requires a result the company cannot substantiate publicly, change the narrative rather than strengthen the language.

Build a public evidence and attribution map

Before outreach, create a working record with the company's appropriate scientific, communications and other reviewers. For each proposed statement, record:

• The exact claim and its intended audience.
• The public document supporting it, with its date and relevant passage.
• Who produced the evidence and which company, asset or study it concerns.
• The qualifications needed to preserve its meaning.
• The appropriate internal reviewer and the approved external wording.

Use the map to identify gaps between what the company wants to communicate and what a reader can verify. This is a proposed editorial practice, not a legal clearance process or a promise that particular wording is permissible.

Check public pages and documents individually. Can a reader find the relevant text, understand its context and identify its source? Test what an engine can retrieve rather than assuming that every PDF, JavaScript page or investor portal is either accessible or invisible. Keep confidential information out of the public evidence plan.

Treat one vendor's audit as an example, not a benchmark

A Presenc AI biotech example reports that one company appeared in 4 of 40 prompts, while its closest-stage direct competitor appeared in 14 of 40. Those counts equal 10% and 35% of that prompt set.

This is one vendor's example, not an industry benchmark or an AuthorityTech client result. The counts alone do not establish representative prompt selection, repeatability, causality or fundraising impact. Use the example to motivate a practical question: what does a defined set of relevant questions reveal about this company's descriptions and source coverage? Do not turn its percentages into a target or an expected return.

Compare publication fit using observed sources

A publication's relevance should follow the narrative and the audience, not a presumed universal hierarchy of outlet prestige.

For a proposed shortlist, inspect actual reporting on the relevant scientific or commercial question. Note the subject matter, depth, attribution and audience. Separately, record which sources appear in the AI answers you audit. An outlet's appearance in one answer is an observation about that answer, not evidence that it will dominate another engine or question.

Compare candidates on concrete fit: does the publication cover this field, reach the intended reader and publish reporting that can explain the specific claim? A specialist article and a broader business profile may serve different jobs. Do not convert that difference into a fixed citation multiplier.

HDMZ's guidance to biotech founders recommends building a strong foundation in trade publications first and amplifying each win. That is an attributed recommendation, not proof that trade coverage accelerates financing or guarantees AI citations.

Seek reporting that carries the actual narrative

Build an outreach brief around the question, the supporting public evidence and the person qualified to explain it. Show why the subject matters to that publication's readers. Make the distinctions in the evidence map available to the reporter; do not rely on a headline to carry every qualification.

Evaluate resulting coverage for accuracy and attribution. Does it explain the company's contribution, or merely list its name? Does it distinguish the company's work from another organization's findings? Are the relevant public sources identifiable?

A press release, an owned explanation and third-party reporting can each have a role. Test their actual presence in answers rather than assigning wire distribution a near-zero weight or declaring owned content incapable of being cited. Publication is an output to inspect, not evidence that discovery or funding has already improved.

Audit answers as separate outcomes

Use a small, documented prompt set tied to the chosen audience. Proposed prompts might ask what the company does, how its stated approach differs from an adjacent approach, and which public sources describe its work. These are audit designs, not reports of measured success.

Record the engine, date, exact question, returned answer and linked sources. Preserve enough context to repeat the test, and do not treat a single run as stable demand or share of market.

Score distinct outcomes separately:

• Accuracy: does the answer preserve the public evidence and its qualifications?
• Mention: is the company named?
• Retrieval: is there observable evidence that the relevant material was accessed? Mark unknown when the interface does not show this.
• Citation: does the answer link or explicitly attribute a supporting source?
• Recommendation: does it actually suggest considering the company, rather than simply describing it?

Use a documented denominator for any share-of-citation measurement. Track inquiries, investor conversations and financing separately. Changes occurring together do not establish that coverage caused them.

Where Machine Relations fits

Machine Relations (MR) is the discipline of earning AI citations and recommendations for a brand by making that brand legible, retrievable, and credible inside AI-driven discovery. Coined by Jaxon Parrott, founder of AuthorityTech, in 2024. AuthorityTech, founded in 2018, is The World's First Machine Relations Agency.

For biotech, the practical plan is a specific narrative, a public evidence map, relevant third-party reporting and a repeatable answer audit. Treat those as coordinated workstreams, not a placement-count ladder or a promised timeline. Strengthen what the company can substantiate, observe what answers actually say, and revise the plan from that evidence.